Johnson & Johnson (NYSE:JNJ) Stock Holdings Lessened by Heartwood Wealth Advisors LLC

Posted by Defense World Staff on Mar 22nd, 2023

Heartwood Wealth Advisors LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,050 shares of the company’s stock after selling 117 shares during the period. Heartwood Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $539,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of JNJ. Sandy Cove Advisors LLC boosted its holdings in shares of Johnson & Johnson by 1.6% during the 3rd quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock valued at $605,000 after acquiring an additional 60 shares in the last quarter. Paces Ferry Wealth Advisors LLC grew its holdings in Johnson & Johnson by 0.7% during the 3rd quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock worth $1,425,000 after acquiring an additional 62 shares during the last quarter. Mason & Associates Inc raised its stake in shares of Johnson & Johnson by 4.9% during the third quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock valued at $215,000 after acquiring an additional 62 shares during the last quarter. Magnolia Capital Advisors LLC lifted its holdings in shares of Johnson & Johnson by 0.7% during the third quarter. Magnolia Capital Advisors LLC now owns 8,883 shares of the company’s stock worth $1,451,000 after purchasing an additional 62 shares during the period. Finally, Oakworth Capital Inc. grew its stake in shares of Johnson & Johnson by 0.3% in the third quarter. Oakworth Capital Inc. now owns 21,363 shares of the company’s stock worth $3,490,000 after purchasing an additional 63 shares during the last quarter. Institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $153.89 on Wednesday. The stock has a 50-day moving average of $161.11 and a 200-day moving average of $167.82. Johnson & Johnson has a one year low of $150.71 and a one year high of $186.69. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77. The company has a market cap of $400.77 billion, a PE ratio of 22.83, a P/E/G ratio of 2.63 and a beta of 0.54.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating the consensus estimate of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The firm had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. During the same quarter in the previous year, the company posted $2.13 earnings per share. The company’s quarterly revenue was down 4.4% on a year-over-year basis. On average, equities research analysts predict that Johnson & Johnson will post 10.5 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st were paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.94%. The ex-dividend date of this dividend was Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is 67.06%.

Insider Transactions at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.35% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent research reports. Guggenheim initiated coverage on Johnson & Johnson in a report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 target price on the stock. Piper Sandler decreased their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Morgan Stanley raised their price target on shares of Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 25th. SVB Leerink decreased their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Finally, Citigroup boosted their target price on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.73.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.